AIEOP
ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA

Presidente
A. Mastronuzzi

Segreteria Scientifica
A. Colombini, T. Perillo, A. Zibaldo

Giornate AIEOP

BOLOGNA
Zanhotel Europa

14-15 Aprile 2025

Sarcomi Parti Molli

Gianni Bisogno

Dipartimento di Salute della Donna e del Bambino
Padova

Disclosures of Name Surname

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
Google	NO	NO	NO	No	NO	No	NO
Apple	NO	NO	NO	No	NO	No	NO
TikTOK	NO	NO	NO	No	NO	No	NO
Amazon	NO	NO	NO	No	NO	No	NO
Microsoft	NO	NO	NO	No	NO	No	NO
~~TESLA~~	NO	NO	NO	No	NO	No	NO
Just Eat	NO	NO	NO	No	NO	No	NO
Glovo	NO	NO	NO	No	NO	No	NO
ALTRE	NO	NO	NO	No	NO	No	NO

Associazione Italiana Ematologia Oncologia Pediatrica STSC Soft Tissue Sarcoma Committee



GDL Sarcomi delle Parti Molli

Componente: BISOGNO GIANNI (Coordinatore)
Ospedale: Padova – Università degli Studi

Componente: Affinita Maria Carmen Simona
Ospedale: Padova – Azienda Ospedaliero Universitaria

Componente: De Leonardis Francesco (Bertolini P)
Ospedale: Bari - A.O.U. Policlinico di Bari

Componente: Manzitti Carla
Ospedale: Genova – Istituto Giannina Gaslini

Componente: Milano Giuseppe
Ospedale: Roma – Ospedale Bambino Gesù

Componente: Perruccio Katia
Ospedale: Perugia – Ospedale Silvestrini

Componente: Chiaravalli Stefano
Ospedale: Milano – Istituto Nazionale Tumori

Consulente: Casanova Michela
Ospedale: Milano – Istituto Nazionale Tumori

Consulente: Alaggio Rita
Ospedale: Padova – Università degli Studi

Consulente: Lucia Tombolan -> Poli Elena
Ospedale: Padova – Istituto di Ricerca Pediatrica Città della Speranza

Consulente: Andrea Ferrari
Ospedale: Milano – Istituto Nazionale Tumori

Coinvolgimento giovani colleghi:

- Federico Mercolini (BO), Veronica Folsi (BS), Daniela Di Carlo (PD), Evelina Miele (OBG), Federica Cennamo (Parma), Virginia Livellara (Genova), Valentina Di Ruscio (OBG), Ida Russo (OBG), ...

Pubblicazioni «nazionali»

1: Fichera G, Cecchin D, Stramare R, Bisogno G, Causin F, Zucchetta P, Giraudo C. Assessment of Lung Nodules in Children With Pediatric Sarcoma Undergoing [18F]-FDG-PET/MR for Staging. Pediatr Blood Cancer. 2025 May;72(5):e31622. doi: 10.1002/pbc.31622. Epub 2025 Feb 24. PMID: 39992159.

2: Di Carlo D, Affinita MC, Poli E, Bisogno G. Systemic therapy in metastatic pediatric rhabdomyosarcoma: a history of challenges and the search for promising approaches. Expert Opin Pharmacother. 2025 Apr;26(6):755-763. doi: 10.1080/14656566.2025.2484319. Epub 2025 Mar 31. PMID: 40129247.

3: Clerici CA, Bernasconi A, Lasalvia P, Bisogno G, Milano GM, Trama A, Chiaravalli S, Bergamaschi L, Casanova M, Massimino M, Ferrari A. Being diagnosed with a rhabdomyosarcoma in the era of artificial intelligence: Whom can we trust? Pediatr Blood Cancer. 2024 Nov;71(11):e31256. doi: 10.1002/pbc.31256. Epub 2024 Aug 11. PMID: 39129151.

4: Motta M, Barresi S, Pizzi S, Bifano D, Lopez Marti J, Garrido-Pontnou M, Flex E, Bruselles A, Giovannoni I, Rotundo G, Fragale A, Tirelli V, Vallese S, Ciolfi A, Bisogno G, Alaggio R, Tartaglia M. RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma-like mesenchymal tumors. J Pathol. 2024 Jun;263(2):166-177. doi: 10.1002/path.6272. Epub 2024 Apr 17. PMID: 38629245.

Studio osservazionale su valutazione della fertilità nei pazienti trattati per RMS

(P.I. MC Affinita)

Disegno dello studio: Studio osservazionale, multicentrico. La durata complessiva prevista dello studio è di 3 anni.

Scopo e Obiettivo dello Studio

a) Valutare la fertilità nei pazienti di sesso maschile con RMS localizzato o metastatico.

b) Valutare se l'aggiunta della terapia di mantenimento con ciclofosfamide a basse dosi rappresenti un rischio aggiuntivo per la fertilità.

Confronteremo i pazienti (>16 anni) trattati con schema standard (9 cicli IVA/IVAdo) (gruppo A) versus quelli che hanno ricevuto lo schema standard + terapia di mantenimento (6 o 12 mesi di ciclofosfamide a basse dosi e vinorelbina) (gruppo B).

Approvato C.E. Padova: 20/7/23

Centri aperti: PD (9), INT MI (3), in approvazione: 15 Centri

Target: 30 pazienti

CENTRI:
Padova (attivato)
Milano (attivato)
Roma "Bambino Gesù"
Torino
Gaslini Genova
Bergamo
Verona
Parma
Meyer Firenze
Perugia
Luigi Vanvitelli Napoli
Santobono Pausilipon
Napoli
Bari
Palermo
Catania
Bologna
Lecce

STUDIO OSSERVAZIONALE *CLINICO-RADIOLOGICO-BIOLOGICO* SU PAZIENTI PEDIATRICI AFFETTI DA SARCOMA DELLE PARTI MOLLI

Approvato dal CD AIEOP

Centro Trial AIEOP ha invitato ai Centri la proposta di adesione
- 17 hanno aderito

Approvato da C.E. Padova (dicembre 2024)

AIEOP ha inviato documentazione ai Centri per approvazione CE
- 2 Centri attivati: Padova, INT Milano

Ministero della Salute
Direzione generale della ricerca e dell'innovazione in sanità
PNRR: M6/C2_CALL 2023 Full Proposal

Finanziato dall'Unione europea
NextGenerationEU

BOLOGNA 14-15 APRILE 2025

Project code: PNRR-TR1-2023-12377677 **Project topic:** C1) Tumori rari: sostegno e potenziamento delle infrastrutture necessarie a sostenere la ricerca

PI / Coordinator: Alaggio Rita **Applicant Institution:** Ospedale pediatrico Bambino Gesù

SAPERE SArcomas in PEdiatric age, a molecular REgistry and network

- Progetto finanziato nella categoria '**Tumori Rari**'
- Capofila: **IRCCS Ospedale Bambino Gesù**
- Unità Operative:
  - Azienda Ospedale – Università di Padova (UO2),
  - ARNAS Civico Di Cristina e Benfratelli Palermo (UO3),
  - Azienda Osped.-Univ. Consorziale, Osp. Pediatrico Giovanni XXIII Bari (UO4)
- Finanziamento: 1.000.000,00 €
- Durata: 24 mesi

Attività

1. **Istituire un database di dati clinici, radiologici, istologici e molecolari dei sarcomi pediatrici**

- Raccogliere e archiviare in modo sistematico i dati clinici, istologici e molecolari dei casi di sarcomi pediatrici provenienti dai diversi centri partecipanti
- Sviluppare un'infrastruttura informatica sicura e accessibile per l'archiviazione e la gestione dei dati

2. **Fondare un tumor board nazionale per i sarcomi pediatrici**

- Creare una piattaforma virtuale per consentire la discussione multidisciplinare a distanza dei casi di sarcomi pediatrici
- Definire i protocolli e le procedure per la presentazione e la valutazione dei casi nel tumor board

3. **Creare un classificatore molecolare dei sarcomi pediatrici**

- Analizzare i dati di trascrittomica dei campioni tumorali per identificare pattern molecolari distintivi
- Sviluppare un algoritmo di classificazione basato sui profili di espressione genica
- Validare il classificatore molecolare su un insieme di dati indipendente

4. **Identificare vie molecolari predittive di comportamento aggressivo**

- Integrare i dati clinici, istologici e molecolari per correlare le caratteristiche tumorali con l'aggressività e la prognosi
- Analizzare le differenze nei profili molecolari tra tumori primitivi e recidive
- Identificare potenziali biomarcatori predittivi di risposta alla terapia e progressione della malattia

5. **Sviluppare nuove raccomandazioni e identificare nuove terapie**

- Effettuare uno screening di piccole molecole su colture cellulari derivate da tumori resistenti
- Valutare l'attività antitumorale di singoli agenti o combinazioni farmacologiche
- Formulare raccomandazioni terapeutiche personalizzate basate sui profili molecolari dei tumori

Associazione Italiana Ematologia Oncologia Pediatrica STSC Soft Tissue Sarcoma Committee



clinical trial updates

Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study

Gianni Bisogno, MD, PhD[1,2]; Veronique Minard-Colin, MD, PhD[3]; Ilaria Zanetti, BSc[2]; Andrea Ferrari, MD[4]; Soledad Gallego, MD, PhD[5]; Raquel Dávila Fajardo, MD, PhD[6,7]; Henry Mandeville, MD[8]; Anna Kelsey, MD[9]; Rita Alaggio, MD[10]; Daniel Orbach, MD, PhD[11]; Sheila Terwisscha van Scheltinga, MD[7]; Gabriela Guillén Burrieza, MD[12]; Myriam Ben-Arush, MD[13]; Heidi Glosli, MD[14]; Peter Mudry, MD[15]; Sima Ferman, MD[16]; Christine Devalck, MD[17]; Anne Sophie Defachelles, MD[18]; Johannes Hendrikus Maria Merks, MD, PhD[7,19]; and Meriel Jenney, MD, PhD[20]

J Clin Oncol 00. © 2023 by American Society of Clinical Oncology

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Gianni Bisogno, Meriel Jenney, Christophe Bergeron, Soledad Gallego Melcón, Andrea Ferrari, Odile Oberlin, Modesto Carli, Michael Stevens, Anna Kelsey, Angela De Paoli, Mark N Gaze, Helene Martelli, Christine Devalck, Johannes H Merks, Myriam Ben-Arush, Heidi Glosli, Julia Chisholm, Daniel Orbach, Veronique Minard-Colin, Gian Luca De Salvo, for the European paediatric Soft tissue sarcoma Study Group

Lancet Oncol 2018; 19: 1061–71

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Gianni Bisogno, Gian Luca De Salvo, Christophe Bergeron, Soledad Gallego Melcón, Johannes H Merks, Anna Kelsey, Helene Martelli, Veronique Minard-Colin, Daniel Orbach, Heidi Glosli, Julia Chisholm, Michela Casanova, Ilaria Zanetti, Christine Devalck, Myriam Ben-Arush, Peter Mudry, Sima Ferman, Meriel Jenney, Andrea Ferrari*, for the European paediatric Soft tissue sarcoma Study Group*

Lancet Oncol 2019; 20: 1566–75

Journal of Clinical Oncology®
An American Society of Clinical Oncology Journal

CLINICAL TRIAL UPDATES | March 07, 2025

Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European *Paediatric* Soft Tissue Sarcoma Study Group RMS 2005 Trial

Authors: Gianni Bisogno, MD, PhD, Julia Chisholm, MD, Raquel Hladun, MD, Gian Luca De Salvo, MD, Florent Guerin, MD, Michela Casanova, MD, Henry Mandeville, MD, Rita Alaggio, MD, Beatrice Coppadoro, BSc, Daniel Orbach, Andrea Ferrari, MD, Rick van Rijn, MD, Anne-Sophie Defachelles, MD, Myriam Ben-Arush, MD, Heidi Glosli, MD, Maja Cesen, MD, Johannes H.M. Merks, MD, PhD, and Véronique Minard-Colin, MD, PhD SHOW FEWER | AUTHORS INFO & AFFILIATIONS



10-year OS 70.8% vs 82.9% (p=0.0099).



10-year DFS 66.5% vs 77.1% (p=0.025)

Mantenimento:
Dosi ?
IV vs orale ?
Durata
Sequele (fertilità e secondi tumori)

Publications by year



- 74 publications total
- 129 EpSSG members with at least 1 publication

FaR-RMS

Frontline and Relapse
RhabdoMyoSarcoma study



Aggiornamento Dicembre 2024

- **Aperte 15/22 nazioni previste**
- **144 Centri**
- **761 pazienti registrati**
- **450 arruolamenti nei trial randomizzati**

(1 paziente può essere arruolato in più trial)

Documenti	Status
PARERE CE–UK	22.07.2019
Parere ISS	18.11.2021
Autorizzazione AIFA	6.12.2021
Reclutamento centri italiani (29)	Fatto
BUDGET ITALIA	Definito
REFERENCE SAPETY INFORMATION	Ricevuto
DATA SHARING POLICY-EpSSG-FaR-RMS	23.02.2023
Contratto AIEOP-Birmingham	**Firmato 08.01.2024**
PARERE FINALE CE Padova	**11.06.2024**
Contratto AIEOP-AOUP	**Firmato 25.06.2024**
Emendamento elenco centri CET Padova (26)	**7.11.2024**
FaR-RMS Trial transition CTIS	**20.11.2024**
Contratto AIEOP-UniPD (CC)	**Firmato 20.01.2025**
Assicurazione	**Pagata 3.3.25**
Contratto UniPD-CRO	**firmato**
Attivazione centri italiani (AIEOP)	**Richiesta**

FaR-RMS
Frontline and Relapse RhabdoMyoSarcoma study

~ 5 anni

Coordinating Sponsor: Birmingham

contratto

FaR-RMS
Frontline and Relapse RhabdoMyoSarcoma study

contratto

Coordinating Centre: Padova

- Compiti amministrativi (es. preparazione protocollo, contatti con i centri,….)
- Coordinamento nazionale raccolta dati
- Raccolta fondi

National Sponsor: AIEOP

- Compiti amministrativi (es. presentazione protocollo, contratti con i centri,….)

contratto

Laboratorio di Padova
Laboratorio OPBG

contratti

contratto

Assicurazione

contratto

CRO

Centri Italiani

Site RTQA Approval

Pre-trial assessment of site's ability to meet trial requirements

- Facility Questionnaire
- Beam Output Audit
- Advanced Technique Credentialing

Mandatory to allow RT randomisation

Individual Case Review

On trial review of all radiotherapy plans – prospective

- RTQA guidelines expand on protocol requirements
- Case submission form, all DICOM-RT data & supporting imaging/reports
- Reviewer feedback

Mandatory for all randomised patients

RTQA Approval (per altri studi)

Site Name		Site Name		Site Name	
AOU Padova	✅	AOU Modena	✅	S.Giovanni Rotondo	
AOU Torino	✅	IRCCS Meyer Firenze		AOU Bari	✅
IRCCS Gaslini Genova	✅	AOU Pisana		ARNAS Palermo	✍️
IRCCS San Matteo Pavia	✅	Ospedale SM Perugia	✅	AOU Catania	✍️
ASST Bergamo	✅	AOU Marche		ARNAS Brotzu Cagliari	✅
IRCCS Milano	✅	IRCCS Gemelli Roma	✅	Ospedale Taranto	
AOU Verona	✅	IRCCS OBG Roma	✅	IRCCS Bologna	
IRCCS Burlo Trieste	✅	AOU Vanvitelli Napoli		AO Cosenza	
AUO Parma		AORN Pausilipon Napoli	✅		

NON SOLO FAR RMS

RMS Work Group

14-15 APRILE 2025

https://www.epssgassociation.it/about/committees/rms-working-group/,256

Call for application for the EpSSG- Benchista initiative

Dear EpSSG members, dear colleagues, dear friends,

The RMS working Group is searching for collaboration for a joint EpSSG-Benchista in initiative.

The Benchista Project:
The International Benchmarking of Childhood Cancer Survival by Stage Project also called BENCHISTA, is a research collaboration between multiple population-based cancer registries (PBCRs) within and outside Europe. The project is designed to understand the reasons of variation in childhood cancer survival rates between countries and to highlight any areas that require improvement.
The project aims to improve understanding of the reasons for variation in childhood cancer survival between countries and to highlight areas that need to be targeted for improvement. Also, to encourage the application of the Toronto Staging Guidelines (TG) by a large number of European and non-European cancer registries (CRs) for the most common solid paediatric cancers.
The project focuses on: medulloblastoma, osteosarcoma, Ewing sarcoma, **rhabdomyosarcoma**, neuroblastoma, and Wilms Tumour diagnosed between 2014-2017.
For more information about the project see here: The BENCHISTA Project | UCL Great Ormond Street Institute of Child Health - UCL – University College London

The EpSSG- BENCHISTA initiative

The main aim is to compare EpSSG clinical trial data with BENCHISTA registry data

We look for

a colleague to be part of the research team with the following characteristics

1. Less than 40 years old
2. EpSSG member for at least two years
3. Demonstrated ability to work independently and deliver results (the candidate should address this point briefly, including a short CV and relevant publications).

Application Submission Notice

Candidates interested in applying must submit their application and Curriculum Vitae, including a list of publications, via email to the EpSSG Secretary, Julia Daragjati, at julia.daragjati@unipd.it by **October 31, 2024**.

Working on «new» RMS entities

(p53, NCOA and/or VGLL rearrangement, EWSR1/FUS:TFCP2 fusions)

- **Call for application to Search for Young Colleagues**: Identify two young professionals **to work on the systematic review**.

The preferred candidates are:

- One pediatric oncologist.
- One lab expert (Biology Panel).

- **RMS Working Group**: Select the candidates and establish a core group for each topic.

NON SOLO RMS

(A. Ferrari)

MYCKIDS: Molecular Identification and Characterization of non-Rhabdomyosarcoma Soft Tissue Sarcoma in Kids, Adolescents and Young Adults: an EpSSG NRSTS study
International sponsorship: Prinses Máxima Center, Utrecht

PI's: M van Noesel, D Orbach, A Ferrari



REACH NRSTS

(**RE**gorafenib in young adults, **A**dolescents and **C**hildren with **H**igh-risk **NRSTS**)

PI: S Gatz, A Ferrari, M Casanova

From phase II/III randomised study to Ib feasibility study (30 patients, all receiving Regorafenib, with two dose levels in a flip-flop design)

OCTOPUS

Optimising **C**ombination **T**herapy f**o**r **P**aediatric, Adolescent and Yo**u**ng Adult Patients with Non-Rhabdomyosarcoma Soft Tissue **S**arcomas

Giornate AIEOP

BOLOGNA 14-15 APRILE 2025

MYCKIDS: Molecular Identification and Characterization of non-Rhabdomyosarcoma Soft Tissue Sarcoma in Kids, Adolescents and Young Adults: an EpSSG NRSTS study
International sponsorship: Prinses Máxima Center, Utrecht

PI's: M van Noesel, D Orbach, A Ferrari



Work packages	Material	Number of cases	Investigations	Coordinators
WP1	Fresh frozen tissue or DNA & RNA	200	WES mRNAseq DNAmeth	Prinses Máxima Center, Utrecht, Netherlands *Bas Tops, Michael Meister*
WP2	FFPE-paraffin embedded tissue	250	GI vs CINSARC vs grading	Centre Léon Bérard, Lyon, France *Franck Tirod, Marie Karanian*
WP3	Fresh viable tissue	30	organoids	Prinses Máxima Center, Utrecht, Netherlands *Bas Tops, Michael Meister*
WP4	Blood plasma	100	liquid biopsies	Royal Marsden, Sutton, UK *Janet Shipley*
WP5	FFPE Posttreatment tissue	40	WES mRNAseq DNAmeth	OPBG Roma + Padova, Italia *Rita Alaggio, Giuseppe Maria Milano*

- 16th May 2024 – official opening (first center PMC)
- 31st May 2024 - first patient enrolled

REACH NRSTS

(**RE**gorafenib in young adults, **A**dolescents and **C**hildren with **H**igh-risk **NRSTS**)

PI: S Gatz, A Ferrari, M Casanova

From phase II/III randomised study to Ib feasibility study (30 patients, all receiving Regorafenib, with two dose levels in a flip-flop design)

Trial question:

Can addition of **Regorafenib** to standard Ifosfamide-Doxorubicine chemotherapy improve outcome in children, adolescents and young adults with high-risk NRSTS?



OCTOPUS

Optimising **C**ombination **T**herapy f**o**r **P**aediatric, Adolescent and Yo**u**ng Adult Patients with Non-Rhabdomyosarcoma Soft Tissue **S**arcomas



Oct 2024 – PMC grant (500.000 €)
Nov 2024 – LOI for FKT – approved
Mar 2025 – sumission for FKT grant (2.000.000 €)

DESMOID ARM



✓ RCT, 1:1, primary endpoint PFS (radiological + clinical response)
✓ 114 pts, assuming 20% PFS difference

Associazione Italiana Ematologia Oncologia Pediatrica STSC Soft Tissue Sarcoma Committee



THE UNIVERSITY OF CHICAGO
PEDIATRIC CANCER DATA COMMONS

INSTRuCT

INternational Soft Tissue saRcoma ConsorTium

CHILDREN'S ONCOLOGY GROUP

EPSSG European Paediatric Soft Tissue Sarcoma Study Group

ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA AIEOP
STSC SOFT TISSUE SARCOMA COMMITTEE

CWS Cooperative Weichteilsarkom Studiengruppe

SOCIÉTÉ INTERNATIONALE D'ONCOLOGIE PÉDIATRIQUE
SIOP
INTERNATIONAL SOCIETY OF PAEDIATRIC ONCOLOGY
MALIGNANT MESENCHYMAL TUMOUR (MMT) COMMITTEE

DATA FOR THE COMMON GOOD

ABOUT PCDC DATA PORTAL PORTFOLIO RESEARCH DONATE

INSTRuCT

Information for Researchers

Cohort Discovery Tool: Log in to the PCDC Data Portal

Data Dictionaries:

Rhabdomyosarcoma Data Dictionary

NRSTS Data Dictionary

Project Requests:

Project Proposal Form

Publication Policy

See all past and ongoing INSTRuCT research projects here.

Research Contact: If you are looking for a research project or if you have a research project that you are interested in conducting with INSTRuCT data, or if you have any questions, please contact Suzi Birz at sbirz@bsd.uchicago.edu.

INSTRuCT Research

Click on a description to view the original project proposal.
(ST) = statisitician

Project Status Key
Approved: Project has been approved by the designated committee; writing not yet underway.
In Progress: Data has been released or writing is underway.
Presented: Project has been presented at a conference but not yet published.
Published: Paper has been published.

INSTRuCT #	Principal Investigator	Description	Project Type	Status	Publication
2024-01	Gianni Bisogno	The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT): the baseline analysis of rhabdomyosarcoma data	WG Research	In Progress	
2023-01	Tim Lautz *Jim Anderson (ST)*	Correlation of clinical and pathologic lymph node staging in RMS of the extremity.	WG Research	In Progress	
2022-10	Monika Sparber-Sauer David Walterhouse *Matthieu Carton (ST)*	Role of adjuvant therapy in large NRSTS or/and IRS II NRSTS	WG Research	Approved	
2022-09	Andrea Ferrari Aaron Weiss *Jim Anderson (ST)*	Response to neoadjuvant chemotherapy vs. chemo-radiotherapy	WG Research	In Progress	
2022-08	Daniel Orbach *Matthieu Carton (ST)*	Nodal tumor spread in pediatric NRSTS, at diagnosis or at relapse according to initial local therapies	WG Research	In Progress	
2022-07	Guido Seitz	Biopsy-Removal-Treatment project of lymph nodes in rhabdomyosarcoma	WG Research	Approved	
2022-06	Simone Hettmer *Beatrice Coppadoro (ST)*	Rhabdomyosarcoma gene fusions between FOXO1 and either PAX3 or PAX7: Correlations with clinical presentation and patient outcomes	WG Research	In Progress	
2022-05	Tim Lautz	Impact of surgical local control on survival in children with metastatic RMS	WG Research	Approved	
2022-04	Dave Rodeberg	Delayed Primary Excision	WG Research	Approved	

41 projects:

- **10 approved**
- **15 in progress**
- **1 withdrawn**
- **15 published**

Prossimi appuntamenti

2025			
Each Month	EpSSG Board	**Virtual Meeting**	Confirmed
May 13-17 (Mon-Fri)	SIOPE Congress (EpSSG Spring meeting & Association Assembly)	**Budapest**	Confirmed
December 4-6 (Wed-Fri)	EpSSG Winter Meeting & Association Assembly	**Athens**	Confirmed
2026			
Each Month	EpSSG Board	**Virtual Meeting**	To be confirmed
April or May	SIOPE Congress (EpSSG Spring meeting & Association Assembly)	**To be decided**	To be decided
December 2-4 (Wed-Fri)	EpSSG Winter Meeting & Association Assembly	**Padova**	Confirmed

RINGRAZIAMENTI

GDL SPM

Membri:
Bisogno Gianni(Coordinatore), Padova
Affinita Maria Carmen Simona, Padova
De Leonardis Francesco, Bari
Manzitti Carla, Genova
Milano Giuseppe, Roma
Perruccio Katia, Perugia
Chiaravalli Stefano, Milano

Consulenti
Casanova Michela, Milano
Alaggio Rita, Roma
Poli Elena, Padova
Andrea Ferrari, Milano

con:
Federico Mercolini (BO), Veronica Folsi (BS), Daniela Di Carlo (PD), Evelina Miele (OBG), Federica Cennamo (Parma), Virginia Livellara (Genova), Valentina Di Ruscio (OBG), Ida Russo (OBG), ...

AIEOP e Centri AIEOP

E naturalmente:
Ilaria Zanetti
Beatrice Coppadoro
Angela Scagnellato
Sandra Mongera

EpSSG Board

INSTRuCT Committee
.....